|
ARHGEF35 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.88279999871577E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.85919995749396E-09 |
| Normal-vs-Stage2 |
4.33560000001609E-06 |
| Normal-vs-Stage3 |
9.91200010957982E-10 |
| Normal-vs-Stage4 |
1.66129998646625E-10 |
| Stage1-vs-Stage2 |
2.352400E-01 |
| Stage1-vs-Stage3 |
1.876170E-01 |
| Stage1-vs-Stage4 |
3.522100E-02 |
| Stage2-vs-Stage3 |
5.221800E-02 |
| Stage2-vs-Stage4 |
1.182060E-02 |
| Stage3-vs-Stage4 |
4.609000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.07879993405913E-10 |
| Normal-vs-AfricanAmerican |
1.629990E-04 |
| Normal-vs-Asian |
1.62879999487942E-08 |
| Caucasian-vs-AfricanAmerican |
4.311200E-01 |
| Caucasian-vs-Asian |
7.672400E-01 |
| AfricanAmerican-vs-Asian |
5.943600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.93450002870111E-09 |
| Normal-vs-Female |
3.07059999649084E-09 |
| Male-vs-Female |
9.488400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.46529999747835E-08 |
| Normal-vs-Age(41-60Yrs) |
1.8174000082638E-09 |
| Normal-vs-Age(61-80Yrs) |
1.77369996468002E-09 |
| Normal-vs-Age(81-100Yrs) |
4.081200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.720800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.538600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.292200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.425200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.880000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.387000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.864900E-03 |
| Classical-VS-Follicular |
9.024300E-02 |
| Classical-VS-Other |
2.866400E-01 |
| Classical-VS-Normal |
5.92259996601285E-09 |
| Tall-VS-Follicular |
2.797900E-04 |
| Tall-VS-Other |
7.339000E-01 |
| Tall-VS-Normal |
1.65220059855642E-11 |
| Follicular-VS-Other |
1.881560E-01 |
| Follicular-VS-Normal |
1.3557000000386E-06 |
| Other-VS-Normal |
4.33180000000144E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.04789998689859E-09 |
| Normal-vs-N1 |
1.83290049804441E-10 |
| N0-vs-N1 |
3.756000E-02 |
|
|
